Stockscreener 앱 받기
4.06
0.98%
-0.04
시간 외 거래:
4.06
전일 마감가:
$4.10
열려 있는:
$4.12
하루 거래량:
198.27K
Relative Volume:
0.89
시가총액:
$243.12M
수익:
$33.48M
순이익/손실:
$-52.70M
주가수익비율:
-3.15
EPS:
-1.2889
순현금흐름:
$-49.45M
1주 성능:
+9.14%
1개월 성능:
-3.56%
6개월 성능:
-10.38%
1년 성능:
+48.72%
1일 변동 폭
$4.05
$4.135
1주일 범위
$3.75
$4.155
52주 변동 폭
$2.20
$5.424
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
명칭
Orchestra Biomed Holdings Inc
전화
646-343-9298
주소
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
4.06 | 245.51M | 33.48M | -52.70M | -49.45M | -1.2889 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 개시 | TD Cowen | Buy |
| 2025-08-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-03-20 | 개시 | BTIG Research | Buy |
| 2025-01-02 | 개시 | Barclays | Overweight |
| 2024-08-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-25 | 개시 | B. Riley Securities | Buy |
| 2024-01-19 | 개시 | Jefferies | Buy |
| 2023-02-24 | 개시 | Piper Sandler | Overweight |
| 2023-02-07 | 개시 | Chardan Capital Markets | Buy |
모두보기
Orchestra Biomed Holdings Inc 주식(OBIO)의 최신 뉴스
OBIO Q1 2026 Earnings: Narrowed Loss as EPS Surpasses Estimates; Stock Posts Modest DeclineHot Market Picks - Newser
Orchestra BioMed Advances FDA Path for Hypertension Device - MyChesCo
Orchestra BioMed Targets 2027 Data for Hypertension Trial - MyChesCo
Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock - Yahoo Finance
Orchestra BioMed director Jason buys $2,493 in stock - Investing.com UK
Orchestra BioMed director Jason buys $2,493 in stock By Investing.com - Investing.com Canada
Orchestra BioMed (OBIO) director adds 665 shares in open-market buy - Stock Titan
Orchestra BioMed Holdings (OBIO) price target increased by 11.30% to 12.68 - MSN
Orchestra BioMed CEO David Hochman buys $18,850 in company stock By Investing.com - Investing.com Nigeria
Orchestra BioMed director Aryeh Jason buys $34,986 in stock By Investing.com - Investing.com Nigeria
Orchestra BioMed CEO David Hochman buys $18,850 in company stock - Investing.com India
Jefferies healthcare fireside chat to feature Orchestra BioMed CEO - Stock Titan
Director at Orchestra BioMed (OBIO) buys 8,971 shares in open market - Stock Titan
Orchestra BioMed (OBIO) director adds 5,000 shares in open-market buy - Stock Titan
B. Riley Cuts Price Target on Orchestra BioMed Holdings to $10 From $12, Keeps Buy Rating - marketscreener.com
Orchestra BioMed director Fain buys $82,600 in shares By Investing.com - Investing.com South Africa
Orchestra BioMed director Fain buys $82,600 in shares - Investing.com UK
Orchestra BioMed (OBIO) director trust buys 20,000 shares - Stock Titan
Orchestra BioMed Holdings, Inc. (OBIO) reports Q1 loss, lags revenue estimates - MSN
Orchestra BioMed Secures Ligand Funding for Pivotal Trials - MyChesCo
H.C. Wainwright Maintains Orchestra BioMed(OBIO.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Orchestra BioMed Secures Medtronic Funding for Hypertension Trial - MyChesCo
Orchestra BioMed Holdings (OBIO) Receives a Buy from H.C. Wainwright - The Globe and Mail
OBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
Orchestra BioMed Holdings, Inc. Stock 12‑Month Price Target Raised to $12.57, Implies 210% Upside - TradingView
Orchestra BioMed Q1 Loss Narrows, Revenue Falls - Moomoo
TradingKey - TradingKey
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates - Investing News Network
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Orchestra BioMed Holdings, Inc._March 31, 2026 - SEC.gov
Press Release: Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates - Moomoo
Orchestra BioMed (NASDAQ: OBIO) Q1 2026 loss, cash and funding update - Stock Titan
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027 - Investing News Network
Orchestra BioMed targets Q3 2026 enrollment for hypertension trial By Investing.com - Investing.com Australia
Orchestra BioMed targets Q3 2026 enrollment for hypertension trial - Investing.com
Orchestra Biomed Holdings Announces Update on Backbeat Global Pivotal Trial Timeline - marketscreener.com
Why Orchestra (OBIO) might be the best kept secret in the market (Grinds Higher) 2026-05-08Stock Idea Sharing Hub - newser.com
Orchestra Biomed Holdings Inc (OBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):